Illumina inks a long-term NGS deal with Dutch company Qiagen
Category: #health  By Pankaj Singh  Date: 2019-10-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Illumina inks a long-term NGS deal with Dutch company Qiagen

The pharmaceutical industry is responsible for treating some of the most critical health issues. The sector produces, develops and markets drugs that could be beneficial to people on a larger scale. However, with growing competition in this profitable industry, pharma companies are now planning ahead with ways to expand their market presence.

One such advancement was made recently by Illumina, Inc. who signed a long-term diagnostics partnership with Qiagen, a Dutch pharmaceutical research company that chose to develop kits for Illumina's hardware, instead of developing its own instruments.

As per the agreement, the two firms intend to collaborate on a series of NGS (next-generation sequencing) based tests in various therapeutic regions within the next 15 years. Reportedly, the move comes along the heels of the latest developments in Qiagen, where the company witnessed Peer Schatz, stepping down as the CEO and Chairman, while the firm missed its third-quarter revenue targets.

Reliable reports cite that the Dutch company has planned to reallocate and reprioritize so that it can free some of its resources, which would help it to better focus on its latest venture, such as holding its in-house work on building NGS-related hardware. However, the company assures that it will maintain its support for GeneReader next-gen system’s customers.

Speaking on the move, Peer Schatz said that the collaboration marks as a landmark strategy for the company and will considerably help progress the use of NGS technologies for making a precise clinical decision.

Illumina, on the other hand, has also made some significant development in the Chinese market, when it obtained its first official clearance from the Chinese government for its next-gen, sequencing systems, enabling the firm to commercialize its MiSeqDx device in various institutions and hospitals for in vitro diagnostic testing in the country.

According to Garret Hampton, Executive VP of Clinical Genomics, Illumina, the approval for selling MiSeqDx in China marks as an important cornerstone for the company as it offers more opportunities for NGS.

Source Credit: https://www.fiercebiotech.com/medtech/illumina-qiagen-ink-15-year-companion-diagnostic-partnership-starting-cancer

 



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...